Transforming growth factor-β in stem cells and tissue homeostasis

Abstract

TGF-β 1–3 are unique multi-functional growth factors that are only expressed in mammals, and mainly secreted and stored as a latent complex in the extracellular matrix (ECM). The biological functions of TGF-β in adults can only be delivered after ligand activation, mostly in response to environmental perturbations. Although involved in multiple biological and pathological processes of the human body, the exact roles of TGF-β in maintaining stem cells and tissue homeostasis have not been well-documented until recent advances, which delineate their functions in a given context. Our recent findings, along with data reported by others, have clearly shown that temporal and spatial activation of TGF-β is involved in the recruitment of stem/progenitor cell participation in tissue regeneration/remodeling process, whereas sustained abnormalities in TGF-β ligand activation, regardless of genetic or environmental origin, will inevitably disrupt the normal physiology and lead to pathobiology of major diseases. Modulation of TGF-β signaling with different approaches has proven effective pre-clinically in the treatment of multiple pathologies such as sclerosis/fibrosis, tumor metastasis, osteoarthritis, and immune disorders. Thus, further elucidation of the mechanisms by which TGF-β is activated in different tissues/organs and how targeted cells respond in a context-dependent way can likely be translated with clinical benefits in the management of a broad range of diseases with the involvement of TGF-β.

Growth factor: Activation in health and disease

Targeting a critical growth factor involved in bone and other tissue remodeling could help treat osteoarthritis and other skeletal disorders. A team led by Zhou Xuedong from Sichuan University in Chengdu, China, and Xu Cao from the Johns Hopkins University School of Medicine in Baltimore, Maryland, USA, review the ways in which temporal and spatial activation of transforming growth factor-β (TGF-β), a multi-functional signaling molecule, are needed for proper tissue development and regulation of stem cells throughout the body. Looking at the skeletal system in particular, the researchers discuss how TGF-β controls the balance between bone resorption and bone formation. Faulty TGF-β signaling can lead to numerous bone-associated disorders, including rare genetic diseases and metastatic cancers. The authors also summarize clinical efforts to modulate TGF-β with drugs for the treatment of osteoarthritis and other conditions.

References

[1] Crane JL, Cao X. Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. J. Clin. Invest., 2014, 124:466-472

[2] Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF beta activation. J. Cell Sci., 2003, 116:217-224

[3] Pfeilschifter J, Bonewald L, Mundy GR. Characterization of the latent transforming growth factor beta complex in bone. J. Bone Miner. Res., 1990, 5:49-58

[4] Pedrozo HA et al Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-beta1 from the extracellular matrix of growth plate chondrocytes. Endocrinology, 1999, 140:5806-5816

[5] Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta, 2008, 1782:197-228

[6] Zhen G et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med., 2013, 19:704-712

[7] Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res., 2009, 19:156-172

[8] Tang Y et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med., 2009, 15:757-765

[9] Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev., 1994, 8:133-146

[10] Javelaud D, Mauviel A. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Int. J. Biochem. Cell Biol., 2004, 36:1161-1165

[11] Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr. Rev., 2002, 23:787-823

[12] Proetzel G et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat. Genet., 1995, 11:409-414

[13] Letterio JJ, Roberts AB. Transforming growth factor-beta1-deficient mice: identification of isoform-specific activities in vivo. J. Leukoc. Biol., 1996, 59:769-774

[14] Sanford LP et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGF beta knockout phenotypes. Development, 1997, 124:2659-2670

[15] Derynck R et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature, 1985, 316:701-705

[16] Dickinson ME et al. Chromosomal localization of seven members of the murine TGF-beta superfamily suggests close linkage to several morphogenetic mutant loci. Genomics, 1990, 6:505-520

[17] Flanders KC et al. Localization and actions of transforming growth factor-beta s in the embryonic nervous system. Development, 1991, 113:183-191

[18] de Martin R et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J., 1987, 6:3673-3677

[19] Kaartinen V et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial–mesenchymal interaction. Nat. Genet., 1995, 11:415-421

[20] Bandyopadhyay B et al. A “traffic control” role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J. Cell Biol., 2006, 172:1093-1105

[21] Kondaiah P et al. cDNA cloning of porcine transforming growth factor-beta 1 mRNAs. Evidence for alternate splicing and polyadenylation. J. Biol. Chem., 1988, 263:18313-18317

[22] Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int. J. Biochem. Cell Biol., 1998, 30:293-298

[23] Qian SW, Kondaiah P, Roberts AB, Sporn MB. cDNA cloning by PCR of rat transforming growth factor beta-1. Nucleic Acids Res., 1990, 18:3059

[24] Derynck R, Jarrett JA, Chen EY, Goeddel DV. The murine transforming growth factor-beta precursor. J. Biol. Chem., 1986, 261:4377-4379

[25] Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R. Processing of transforming growth factor beta 1 precursor by human furin convertase. J. Biol. Chem., 1995, 270:10618-10624

[26] Manning AM, Auchampach JA, Drong RF, Slightom JL. Cloning of a canine cDNA homologous to the human transforming growth factor-beta 1-encoding gene. Gene, 1995, 155:307-308

[27] Sengle G, Ono RN, Sasaki T, Sakai LY. Prodomains of transforming growth factor beta (TGF beta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J. Biol. Chem., 2011, 286:5087-5099

[28] Brunner AM, Marquardt H, Malacko AR, Lioubin MN, Purchio AF. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J. Biol. Chem., 1989, 264:13660-13664

[29] Mittl PR et al. The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding. Protein Sci., 1996, 5:1261-1271

[30] Gray AM, Mason AJ. Requirement for activin A and transforming growth factor—beta 1 pro-regions in homodimer assembly. Science, 1990, 247:1328-1330

[31] Oklu R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem. J., 2000, 352:601-610

[32] Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J., 1996, 15:245-253

[33] Mangasser-Stephan K, Gressner AM. Molecular and functional aspects of latent transforming growth factor-beta binding protein: just a masking protein? Cell Tissue Res., 1999, 297:363-370

[34] Koli K, Saharinen J, Karkkainen M, Keski-Oja J. Novel non-TGF-beta-binding splice variant of LTBP-4 in human cells and tissues provides means to decrease TGF-beta deposition. J. Cell Sci., 2001, 114:2869-2878

[35] Bismar H et al. Transforming growth factor beta (TGF-beta) levels in the conditioned media of human bone cells: relationship to donor age, bone volume, and concentration of TGF-beta in human bone matrix in vivo. Bone, 1999, 24:565-569

[36] Roberts AB, Frolik CA, Anzano MA, Sporn MB. Transforming growth factors from neoplastic and nonneoplastic tissues. Fed. Proc., 1983, 42:2621-2626

[37] Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc. Natl. Acad. Sci. USA, 1985, 82:2267-2271

[38] Jenkins G. The role of proteases in transforming growth factor-beta activation. Int. J. Biochem. Cell Biol., 2008, 40:1068-1078

[39] Munger JS et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 1999, 96:319-328

[40] Shi M et al. Latent TGF-beta structure and activation. Nature, 2011, 474:343-349

[41] Derynck R., Miyazono K. The TGF-[beta] Family (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2008.

[42] Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J. Cell Biol., 1989, 109:309-315

[43] Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev., 2000, 14:163-176

[44] Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell, 1997, 91:439-442

[45] Taipale J, Miyazono K, Heldin CH, Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J. Cell Biol., 1994, 124:171-181

[46] Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol., 1988, 106:1659-1665

[47] Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem., 1986, 261:4337-4345

[48] Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem., 2001, 276:17058-17062

[49] Bugge TH et al. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell, 1996, 87:709-719

[50] Murphy-Ullrich JE, Mosher DF. Localization of thrombospondin in clots formed in situ. Blood, 1985, 66:1098-1104

[51] Raugi GJ, Olerud JE, Gown AM. Thrombospondin in early human wound tissue. J. Invest. Dermatol., 1987, 89:551-554

[52] Reed MJ et al. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J. Histochem. Cytochem., 1993, 41:1467-1477

[53] DiPietro LA et al. Thrombospondin 1 synthesis and function in wound repair. Am. J. Pathol., 1996, 148:1851-1860

[54] Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am. J. Pathol., 2002, 161:831-839

[55] Adams JC, Lawler J. The thrombospondins. Int. J. Biochem. Cell Biol., 2004, 36:961-968

[56] Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am. J. Pathol., 2000, 157:1353-1363

[57] Hugo C. The thrombospondin 1-TGF-beta axis in fibrotic renal disease. Nephrol. Dial. Transplant., 2003, 18:1241-1245

[58] Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes, 2007, 56:2982-2989

[59] Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol., 1993, 122:923-932

[60] Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor. Rev., 2000, 11:59-69

[61] Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. J. Biol. Chem., 2004, 279:38032-38039

[62] Walton KL et al. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J. Biol. Chem., 2010, 285:17029-17037

[63] Sweetwyne MT, Murphy-Ullrich JE. Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms. Matrix Biol., 2012, 31:178-186

[64] Crawford SE et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell, 1998, 93:1159-1170

[65] Ludlow A et al. Characterization of integrin beta6 and thrombospondin-1 double-null mice. J. Cell Mol. Med., 2005, 9:421-437

[66] Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose. J. Am. Soc. Nephrol., 2001, 12:703-712

[67] Wang S, Shiva S, Poczatek MH, Darley-Usmar V, Murphy-Ullrich JE. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells. J. Biol. Chem., 2002, 277:9880-9888

[68] Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose upregulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J. Biol. Chem., 2004, 279:34311-34322

[69] Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem. Biophys. Res. Commun., 2006, 339:633-641

[70] Belmadani S et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am. J. Pathol., 2007, 171:777-789

[71] Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE. Blockade of TSP1-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am. J. Pathol., 2011, 178:2573-2586

[72] Yehualaeshet T et al. A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat. Am. J. Respir. Cell Mol. Biol., 2000, 23:204-212

[73] Chen Y et al. A TSP-1 synthetic peptide inhibits bleomycin-induced lung fibrosis in mice. Exp. Toxicol. Pathol., 2009, 61:59-65

[74] Nor JE et al. Activation of latent TGF-beta1 by thrombospondin-1 is a major component of wound repair. Oral. Biosci. Med., 2005, 2:153-161

[75] Sakai K et al. Thrombospondin-1 promotes fibroblast-mediated collagen gel contraction caused by activation of latent transforming growth factor beta-1. J. Dermatol. Sci., 2003, 31:99-109

[76] Chipev CC et al. Myofibroblast phenotype and apoptosis in keloid and palmar fibroblasts in vitro. Cell Death Differ., 2000, 7:166-176

[77] Mimura Y et al. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am. J. Pathol., 2005, 166:1451-1463

[78] Chen Y et al. Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. Fibrogenes. Tissue Repair, 2011, 4:9

[79] van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res., 2001, 305:285-298

[80] Nishimura SL. Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am. J. Pathol., 2009, 175:1362-1370

[81] Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur. J. Cell Biol., 2008, 87:601-615

[82] Yang Z et al. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J. Cell Biol., 2007, 176:787-793

[83] Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J. Histochem. Cytochem., 1993, 41:1521-1527

[84] Breuss JM et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci., 1995, 108:2241-2251

[85] Miller LA, Barnett NL, Sheppard D, Hyde DM. Expression of the beta6 integrin subunit is associated with sites of neutrophil influx in lung epithelium. J. Histochem. Cytochem., 2001, 49:41-48

[86] Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J. Clin. Invest., 1992, 90:1-7

[87] Wang A, Yokosaki Y, Ferrando R, Balmes J, Sheppard D. Differential regulation of airway epithelial integrins by growth factors. Am. J. Respir. Cell Mol. Biol., 1996, 15:664-672

[88] Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J. Cell Biol., 2004, 165:723-734

[89] Yoshinaga K et al. Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. Proc. Natl. Acad. Sci. USA, 2008, 105:18758-18763

[90] Ahamed J et al. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1. Blood, 2008, 112:3650-3660

[91] Pretorius M et al. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation, 2007, 116:I1-7

[92] Aoki K et al. Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burns. . Burns, 2001, 27:569-575

[93] Christ G et al. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication. J. Thromb. Haemost., 2005, 3:233-239

[94] Gando S. Disseminated intravascular coagulation in trauma patients. Semin. Thromb. Hemost., 2001, 27:585-592

[95] Kluft C et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand. J. Clin. Lab. Invest., 1985, 45:605-610

[96] Rahr HB, Sorensen JV, Larsen JF, Jensen FS, Bredahl C. Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. Haemostasis, 1995, 25:248-256

[97] Seeber C, Hiller E, Holler E, Kolb HJ. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb. Res., 1992, 66:373-383

[98] Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA, 1999, 282:2035-2042

[99] Mu D et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol., 2002, 157:493-507

[100] Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100:9482-9487

[101] Brooks PC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell, 1996, 85:683-693

[102] Scaffidi AK et al. alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGF beta) type II receptor to potentiate the proliferative effects of TGFbeta1 in living human lung fibroblasts. J. Biol. Chem., 2004, 279:37726-37733

[103] Yehualaeshet T et al. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am. J. Pathol., 1999, 155:841-851

[104] Wang B et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology, 2007, 46:1404-1412

[105] Henderson NC et al. Targeting of alpha V integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med., 2013, 19:1617-1624

[106] Teitelbaum SL. Bone resorption by osteoclasts. Science, 2000, 289:1504-1508

[107] Hering S et al. TGFbeta1 and TGFbeta2 mRNA and protein expression in human bone samples. Exp. Clin. Endocrinol. Diabetes, 2001, 109:217-226

[108] Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem. Biophys. Res. Commun., 1989, 158:817-823

[109] Oursler MJ. Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J. Bone Miner. Res., 1994, 9:443-452

[110] Pfeilschifter J, Mundy GR. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA, 1987, 84:2024-2028

[111] Wu X et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell, 2010, 7:571-580

[112] Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J. Clin. Invest., 1994, 93:892-899

[113] Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol., 1996, 10:1077-1083

[114] Proell V et al. TGF-beta dependent regulation of oxygen radicals during transdifferentiation of activated hepatic stellate cells to myofibroblastoid cells. Comp. Hepatol., 2007, 6:1

[115] Boudreau HE, Emerson SU, Korzeniowska A, Jendrysik MA, Leto TL. Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress. J. Virol., 2009, 83:12934-12946

[116] Statius van Eps RG, LaMuraglia GM. Photodynamic therapy inhibits transforming growth factor beta activity associated with vascular smooth muscle cell injury. J. Vasc. Surg., 1997, 25:1044-1052

[117] Wang L, Clutter S, Benincosa J, Fortney J, Gibson LF. Activation of transforming growth factor-beta1/p38/Smad3 signaling in stromal cells requires reactive oxygen species-mediated MMP-2 activity during bone marrow damage. Stem Cells, 2005, 23:1122-1134

[118] Jobling MF et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat. Res., 2006, 166:839-848

[119] Derynck R. TGF-beta-receptor-mediated signaling. Trends Biochem. Sci., 1994, 19:548-553

[120] Schmierer B, Hill CS. TGF beta-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol., 2007, 8:970-982

[121] Derynck R, Feng XH. TGF-beta receptor signaling. Biochim. Biophys. Acta, 1997, 1333:F105-150

[122] ten Dijke P, Miyazono K, Heldin CH. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr. Opin. Cell Biol., 1996, 8:139-145

[123] Chai Y, Ito Y, Han J. TGF-beta signaling and its functional significance in regulating the fate of cranial neural crest cells. Crit. Rev. Oral. Biol. Med., 2003, 14:78-88

[124] de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev., 2004, 15:1-11

[125] Esparza-Lopez J et al. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J. Biol. Chem., 2001, 276:14588-14596

[126] Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell, 1993, 73:1435-1444

[127] Yamashita H et al. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J. Biol. Chem., 1994, 269:1995-2001

[128] Cheifetz S et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem., 1992, 267:19027-19030

[129] Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev., 2005, 19:2783-2810

[130] Moustakas A, Heldin CH. The regulation of TGF beta signal transduction. Development, 2009, 136:3699-3714

[131] Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003, 425:577-584

[132] Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol., 2005, 21:659-693

[133] Dennler S et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J., 1998, 17:3091-3100

[134] Zawel L et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell, 1998, 1:611-617

[135] Katagiri T et al. Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells, 2002, 7:949-960

[136] Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J. Biol. Chem., 2002, 277:4883-4891

[137] Morikawa M et al. ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif. Nucleic Acids Res., 2011, 39:8712-8727

[138] Descargues P et al. IKKalpha is a critical coregulator of a Smad4-independent TGF beta-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proc. Natl. Acad. Sci. USA, 2008, 105:2487-2492

[139] Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell, 2010, 39:373-384

[140] Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature, 2008, 454:56-61

[141] Hinck AP. Structural studies of the TGF-betas and their receptors—insights into evolution of the TGF-beta superfamily. FEBS Lett., 2012, 586:1860-1870

[142] Attisano L, Wrana JL, Montalvo E, Massague J. Activation of signalling by the activin receptor complex. Mol. Cell Biol., 1996, 16:1066-1073

[143] Massague J. TGF-beta signal transduction. Annu. Rev. Biochem., 1998, 67:753-791

[144] Liu F, Ventura F, Doody J, Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell Biol., 1995, 15:3479-3486

[145] Nishitoh H et al. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J. Biol. Chem., 1996, 271:21345-21352

[146] Nohno T et al. Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J. Biol. Chem., 1995, 270:22522-22526

[147] Koenig BB et al. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol. Cell Biol., 1994, 14:5961-5974

[148] Penton A et al. Identification of two bone morphogenetic protein type I receptors in Drosophila and evidence that Brk25D is a decapentaplegic receptor. Cell, 1994, 78:239-250

[149] Yamashita H et al. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J. Cell Biol., 1995, 130:217-226

[150] Bharathy S, Xie W, Yingling JM, Reiss M. Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. Cancer Res., 2008, 68:1656-1666

[151] Daly AC, Randall RA, Hill CS. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol. Cell Biol., 2008, 28:6889-6902

[152] Goumans MJ et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J., 2002, 21:1743-1753

[153] Liu IM et al. TGF beta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGF beta switch. EMBO J., 2009, 28:88-98

[154] Wrighton KH, Lin X, Yu PB, Feng XH. Transforming growth factor {beta} can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J. Biol. Chem., 2009, 284:9755-9763

[155] Gronroos E et al. Transforming growth factor beta inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1/5-Smad3 complexes. Mol. Cell Biol., 2012, 32:2904-2916

[156] Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J., 2000, 19:1745-1754

[157] Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev., 2000, 11:5-13

[158] Silvestri C et al. Genome-wide identification of Smad/Foxh1 targets reveals a role for Foxh1 in retinoic acid regulation and forebrain development. Dev. Cell, 2008, 14:411-423

[159] Massague J, Gomis RR. The logic of TGF beta signaling. FEBS Lett., 2006, 580:2811-2820

[160] Labbe E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol. Cell, 1998, 2:109-120

[161] Teo AK et al. Pluripotency factors regulate definitive endoderm specification through eomesodermin. Genes Dev., 2011, 25:238-250

[162] Mullen AC et al. Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell, 2011, 147:565-576

[163] Suzuki A et al. Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. Proc. Natl. Acad. Sci. USA, 2006, 103:10294-10299

[164] Vallier L et al. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development, 2009, 136:1339-1349

[165] Ross S, Hill CS. How the Smads regulate transcription. Int. J. Biochem. Cell Biol., 2008, 40:383-408

[166] van Grunsven LA, Verstappen G, Huylebroeck D, Verschueren K. Smads and chromatin modulation. Cytokine Growth Factor Rev., 2005, 16:495-512

[167] Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev., 1998, 12:2153-2163

[168] Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev., 1998, 12:2114-2119

[169] Beyer TA, Narimatsu M, Weiss A, David L, Wrana JL. The TGF beta superfamily in stem cell biology and early mammalian embryonic development. Biochim. Biophys. Acta, 2013, 1830:2268-2279

[170] Watanabe M, Masuyama N, Fukuda M, Nishida E. Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal. EMBO Rep., 2000, 1:176-182

[171] Xu L, Kang Y, Col S, Massague J. Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGF beta signaling complexes in the cytoplasm and nucleus. Mol. Cell, 2002, 10:271-282

[172] Hill CS. Nucleocytoplasmic shuttling of Smad proteins. Cell Res., 2009, 19:36-46

[173] Varelas X et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat. Cell Biol., 2008, 10:837-848

[174] Varelas X et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev. Cell, 2010, 19:831-844

[175] Lin X et al. PPM1A functions as a Smad phosphatase to terminate TGF beta signaling. Cell, 2006, 125:915-928

[176] Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res., 2009, 19:8-20

[177] Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol., 2003, 5:410-421

[178] Hayashi H et al. The MAD-related protein Smad7 associates with the TGF beta receptor and functions as an antagonist of TGF beta signaling. Cell, 1997, 89:1165-1173

[179] Nakao A et al. Identification of Smad7, a TGF beta-inducible antagonist of TGF-beta signalling. Nature, 1997, 389:631-635

[180] Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature, 1999, 400:687-693

[181] Gao S et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol. Cell, 2009, 36:457-468

[182] Soond SM, Chantry A. Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGF beta signalling and EMT. Oncogene, 2011, 30:2451-2462

[183] Fuentealba LC et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell, 2007, 131:980-993

[184] Alarcon C et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell, 2009, 139:757-769

[185] Qiu T et al. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat. Cell Biol., 2010, 12:224-234

[186] Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J. Cell Sci., 2005, 118:3573-3584

[187] Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res., 2009, 19:128-139

[188] Lee MK et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J., 2007, 26:3957-3967

[189] Sorrentino A et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol., 2008, 10:1199-1207

[190] Yamashita M et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell, 2008, 31:918-924

[191] Bhowmick NA et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell, 2001, 12:27-36

[192] Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol. Biol. Cell, 2002, 13:902-914

[193] Ozdamar B et al. Regulation of the polarity protein Par6 by TGF beta receptors controls epithelial cell plasticity. Science, 2005, 307:1603-1609

[194] Vardouli L, Moustakas A, Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. J. Biol. Chem., 2005, 280:11448-11457

[195] Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem., 2000, 275:36803-36810

[196] Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol. Biol. Cell, 2001, 12:3328-3339

[197] Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol., 2007, 178:437-451

[198] Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-beta-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasion. J. Cell Sci., 2012, 125:1259-1273

[199] Ikushima H, Miyazono K. TGF-beta signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-beta. Cell Tissue Res., 2012, 347:37-49

[200] Vincent T et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial–mesenchymal transition. Nat. Cell Biol., 2009, 11:943-950

[201] Kim KK et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Invest., 2009, 119:213-224

[202] Zhou B et al. Interactions between beta-catenin and transforming growth factor-beta signaling pathways mediate epithelial–mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J. Biol. Chem., 2012, 287:7026-7038

[203] Edlund S et al. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol. Cell Biol., 2005, 25:1475-1488

[204] Singh AM et al. Signaling network cross talk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem. Cell, 2012, 10:312-326

[205] Niimi H, Pardali K, Vanlandewijck M, Heldin CH, Moustakas A. Notch signaling is necessary for epithelial growth arrest by TGF-beta. J. Cell Biol., 2007, 176:695-707

[206] Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J., 2004, 23:1155-1165

[207] Aoyagi-Ikeda K et al. Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-{beta}-Smad3 pathway. Am. J. Respir. Cell Mol. Biol., 2011, 45:136-144

[208] Ohashi S et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res., 2011, 71:6836-6847

[209] Gotzmann J et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene, 2006, 25:3170-3185

[210] Fischer AN et al. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene, 2007, 26:3395-3405

[211] Xue G et al. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov., 2012, 2:248-259

[212] Ferrari G et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science, 1998, 279:1528-1530

[213] Takahashi T et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med., 1999, 5:434-438

[214] Lagasse E et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med., 2000, 6:1229-1234

[215] Orlic D et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA, 2001, 98:10344-10349

[216] Kale S et al. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J. Clin. Invest., 2003, 112:42-49

[217] Wojakowski W, Landmesser U, Bachowski R, Jadczyk T, Tendera M. Mobilization of stem and progenitor cells in cardiovascular diseases. Leukemia, 2012, 26:23-33

[218] Krankel N, Spinetti G, Amadesi S, Madeddu P. Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol. Ther., 2011, 129:62-81

[219] Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell, 2011, 9:11-15

[220] Zaidi M. Skeletal remodeling in health and disease. Nat. Med., 2007, 13:791-801

[221] Bianco P et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med., 2013, 19:35-42

[222] Xian L et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med., 2012, 18:1095-1101

[223] Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-beta1 to the bone. Endocr. Rev., 2005, 26:743-774

[224] Wan M et al. Injury-activated transforming growth factor beta controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells, 2012, 30:2498-2511

[225] Gao P et al. Functional effects of TGF-beta1 on mesenchymal stem cell mobilization in cockroach allergen-induced asthma. J. Immunol., 2014, 192:4560-4570

[226] Lee CH et al. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet, 2010, 376:440-448

[227] Shinojima N et al. TGF-beta mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res., 2013, 73:2333-2344

[228] Thomson JA et al. Embryonic stem cell lines derived from human blastocysts. Science, 1998, 282:1145-1147

[229] Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell, 2003, 115:281-292

[230] Chen X et al. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature, 1997, 389:85-89

[231] Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J., 2001, 20:2254-2272

[232] Liu D, Black BL, Derynck R. TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev., 2001, 15:2950-2966

[233] Choy L, Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J. Biol. Chem., 2003, 278:9609-9619

[234] Xu RH et al. NANOG is a direct target of TGF beta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell, 2008, 3:196-206

[235] Yoon SJ, Wills AE, Chuong E, Gupta R, Baker JC. HEB and E2A function as SMAD/FOXH1 cofactors. Genes Dev., 2011, 25:1654-1661

[236] Xi Q et al. A poised chromatin platform for TGF-beta access to master regulators. Cell, 2011, 147:1511-1524

[237] Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS. Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol. Cell, 2011, 43:85-96

[238] Dupont S et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell, 2005, 121:87-99

[239] Aragon E et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev., 2011, 25:1275-1288

[240] Lonn P et al. PARP-1 attenuates Smad-mediated transcription. Mol. Cell, 2010, 40:521-532

[241] Orkin SH, Hochedlinger K. Chromatin connections to pluripotency and cellular reprogramming. Cell, 2011, 145:835-850

[242] Young RA. Control of the embryonic stem cell state. Cell, 2011, 144:940-954

[243] Chen X et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell, 2008, 133:1106-1117

[244] Oshimori N, Fuchs E. Paracrine TGF-beta signaling counterbalances BMP-mediated repression in hair follicle stem cell activation. Cell Stem Cell, 2012, 10:63-75

[245] Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Stem Cells, 2007, 25:2896-2902

[246] Shi S et al. The efficacy of mesenchymal stem cells to regenerate and repair dental structures. Orthod. Craniofac. Res., 2005, 8:191-199

[247] Boland GM, Perkins G, Hall DJ, Tuan RS. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J. Cell Biochem., 2004, 93:1210-1230

[248] Jian H et al. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev., 2006, 20:666-674

[249] Baksh D, Boland GM, Tuan RS. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J. Cell Biochem., 2007, 101:1109-1124

[250] Liu Z, Tang Y, Qiu T, Cao X, Clemens TL. A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J. Biol. Chem., 2006, 281:17156-17163

[251] Roelen BA, Dijke P. Controlling mesenchymal stem cell differentiation by TGF Beta family members. J. Orthop. Sci., 2003, 8:740-748

[252] Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J., 2004, 23:552-563

[253] Lin X et al. Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription. Mol. Cell Biol., 2003, 23:9081-9093

[254] Tseng YH et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature, 2008, 454:1000-1004

[255] Kurpinski K et al. Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells. Stem Cells, 2010, 28:734-742

[256] Yamazaki S et al. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood, 2009, 113:1250-1256

[257] Larsson J et al. TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood, 2003, 102:3129-3135

[258] Larsson J, Blank U, Klintman J, Magnusson M, Karlsson S. Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-beta signaling in vivo. Exp. Hematol., 2005, 33:592-596

[259] Kale VP, Vaidya AA. Molecular mechanisms behind the dose-dependent differential activation of MAPK pathways induced by transforming growth factor-beta1 in hematopoietic cells. Stem Cells Dev., 2004, 13:536-547

[260] Yamazaki S et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell, 2011, 147:1146-1158

[261] Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell, 2010, 6:265-278

[262] Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science, 1992, 255:1707-1710

[263] Falk S et al. Brain area-specific effect of TGF-beta signaling on Wnt-dependent neural stem cell expansion. Cell Stem Cell, 2008, 2:472-483

[264] Gage FH. Mammalian neural stem cells. Science, 2000, 287:1433-1438

[265] Flanders KC, Ren RF, Lippa CF. Transforming growth factor-betas in neurodegenerative disease. Prog. Neurobiol., 1998, 54:71-85

[266] Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions. J. Neurochem., 2000, 75:2227-2240

[267] Aigner L, Bogdahn U. TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res, 2008, 331:225-241

[268] Dhandapani KM, Brann DW. Transforming growth factor-beta: a neuroprotective factor in cerebral ischemia. Cell Biochem. Biophys., 2003, 39:13-22

[269] Krieglstein K, Strelau J, Schober A, Sullivan A, Unsicker K. TGF-beta and the regulation of neuron survival and death. J. Physiol., 2002, 96:25-30

[270] Wachs FP et al. Transforming growth factor-beta1 is a negative modulator of adult neurogenesis. J. Neuropathol. Exp. Neurol., 2006, 65:358-370

[271] Battista D, Ferrari CC, Gage FH, Pitossi FJ. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur. J. Neurosci., 2006, 23:83-93

[272] Docagne F et al. Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Mol. Cell Neurosci., 2002, 21:634-644

[273] Fuchs E. Scratching the surface of skin development. Nature, 2007, 445:834-842

[274] Hsu YC, Pasolli HA, Fuchs E. Dynamics between stem cells, niche, and progeny in the hair follicle. Cell, 2011, 144:92-105

[275] Plikus MV et al. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. Nature, 2008, 451:340-344

[276] Foitzik K et al. Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J., 2000, 14:752-760

[277] Soma T, Dohrmann CE, Hibino T, Raftery LA. Profile of transforming growth factor-beta responses during the murine hair cycle. J. Invest. Dermatol., 2003, 121:969-975

[278] Foitzik K, Paus R, Doetschman T, Dotto GP. The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis. Dev. Biol., 1999, 212:278-289

[279] Chang C, Eggen BJ, Weinstein DC, Brivanlou AH. Regulation of nodal and BMP signaling by tomoregulin-1 (X7365) through novel mechanisms. Dev. Biol., 2003, 255:1-11

[280] Campion DR. The muscle satellite cell: a review. Int. Rev. Cytol., 1984, 87:225-251

[281] Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol. Rev., 2004, 84:209-238

[282] Peault B et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol. Ther., 2007, 15:867-877

[283] Wang H et al. Bmp signaling at the tips of skeletal muscles regulates the number of fetal muscle progenitors and satellite cells during development. Dev. Cell, 2010, 18:643-654

[284] Collins CA et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell, 2005, 122:289-301

[285] Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science, 2003, 302:1575-1577

[286] Brack AS et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science, 2007, 317:807-810

[287] Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature, 2008, 454:528-532

[288] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126:663-676

[289] Ichida JK et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell, 2009, 5:491-503

[290] Maherali N, Hochedlinger K. Tgf beta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr. Biol., 2009, 19:1718-1723

[291] Lin T et al. A chemical platform for improved induction of human iPSCs. Nat. Methods, 2009, 6:805-808

[292] Li R et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell, 2010, 7:51-63

[293] Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. EMBO J., 2011, 30:823-834

[294] Miyoshi N et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell, 2011, 8:633-638

[295] Subramanyam D et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat. Biotechnol., 2011, 29:443-448

[296] Samavarchi-Tehrani P et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell, 2010, 7:64-77

[297] Moss ML. Studies of the acellular bone of teleost fish. V. Histology and mineral homeostasis of fresh-water species. Acta Anat., 1965, 60:262-276

[298] Weiss RE, Watabe N. Studies on the biology of fish bone. III. Ultrastructure of osteogenesis and resorption in osteocytic (cellular) and anosteocytic (acellular) bones. Calcif. Tissue Int., 1979, 28:43-56

[299] Glowacki J, Cox KA, O'Sullivan J, Wilkie D, Deftos LJ. Osteoclasts can be induced in fish having an acellular bony skeleton. Proc. Natl. Acad. Sci. USA, 1986, 83:4104-4107

[300] Witten PE, Huysseune A. A comparative view on mechanisms and functions of skeletal remodelling in teleost fish, with special emphasis on osteoclasts and their function. Biol. Rev. Camb. Philos. Soc., 2009, 84:315-346

[301] Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann. N. Y. Acad. Sci., 2007, 1116:281-290

[302] Kamioka H, Honjo T, Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone, 2001, 28:145-149

[303] Verborgt O, Tatton NA, Majeska RJ, Schaffler MB. Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation? J. Bone Miner. Res., 2002, 17:907-914

[304] Xiong J et al. Matrix-embedded cells control osteoclast formation. Nat. Med., 2011, 17:1235-1241

[305] Nakashima T et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med., 2011, 17:1231-1234

[306] van Bezooijen RL et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med., 2004, 199:805-814

[307] Bellido T et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology, 2005, 146:4577-4583

[308] Robling AG et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem., 2008, 283:5866-5875

[309] Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone, 2005, 37:148-158

[310] Krause C et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J. Biol. Chem., 2010, 285:41614-41626

[311] Li X et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem., 2005, 280:19883-19887

[312] Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem., 2005, 280:26770-26775

[313] Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem., 2010, 285:25103-25108

[314] Li Y et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 2007, 109:3839-3848

[315] Kacena MA et al. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J. Bone Miner. Res., 2004, 19:652-660

[316] Hume DA. Differentiation and heterogeneity in the mononuclear phagocyte system. Mucosal Immunol., 2008, 1:432-441

[317] Andersen TL et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am. J. Pathol., 2009, 174:239-247

[318] Chang MK et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J. Immunol., 2008, 181:1232-1244

[319] Morikawa S et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med., 2009, 206:2483-2496

[320] Park D et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell, 2012, 10:259-272

[321] Omatsu Y et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity, 2010, 33:387-399

[322] Kunisaki Y et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature, 2013, 502:637-643

[323] Mendez-Ferrer S et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature, 2010, 466:829-834

[324] Ono N et al. Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. Dev. Cell, 2014, 29:330-339

[325] Zheng Y, Geiger H. HSPCs get their motors running for asymmetric fate choice. Cell Stem Cell, 2014, 14:1-2

[326] Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature, 2012, 481:457-462

[327] Lapraz F et al. RTK and TGF-beta signaling pathways genes in the sea urchin genome. Dev. Biol., 2006, 300:132-152

[328] Neidlinger-Wilke C et al. Human osteoblasts from younger normal and osteoporotic donors show differences in proliferation and TGF beta-release in response to cyclic strain. J. Biomech., 1995, 28:1411-1418

[329] Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem., 2002, 277:21352-21360

[330] Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell, 2006, 126:677-689

[331] Kim JS et al. Transforming growth factor-beta1 regulates macrophage migration via RhoA. Blood, 2006, 108:1821-1829

[332] Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med., 2005, 11:76-81

[333] Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. USA, 2008, 105:20764-20769

[334] Kreja L et al. Non-resorbing osteoclasts induce migration and osteogenic differentiation of mesenchymal stem cells. J. Cell Biochem., 2010, 109:347-355

[335] Sanchez-Fernandez MA, Gallois A, Riedl T, Jurdic P, Hoflack B. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PLoS ONE, 2008, 3:e3537

[336] Xie H et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med., 2014, 20:1270-1278

[337] Zhao C et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab., 2006, 4:111-121

[338] Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba. Found. Symp., 1988, 136:42-60

[339] Sacchetti B et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell, 2007, 131:324-336

[340] Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res., 2000, 61:364-370

[341] Negishi-Koga T et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med., 2011, 17:1473-1480

[342] Chim SM et al. Angiogenic factors in bone local environment. Cytokine Growth Factor Rev., 2013, 24:297-310

[343] Seghezzi G et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol., 1998, 141:1659-1673

[344] Beck L Jr., D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J., 1997, 11:365-373

[345] Klein S et al. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol. Biol. Cell, 1993, 4:973-982

[346] Klein S, Bikfalvi A, Birkenmeier TM, Giancotti FG, Rifkin DB. Integrin regulation by endogenous expression of 18-kDa fibroblast growth factor-2. J. Biol. Chem., 1996, 271:22583-22590

[347] Sabbieti MG et al. Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase. Cell Tissue Res., 2005, 319:267-278

[348] Sobue T et al. Regulation of fibroblast growth factor 2 and fibroblast growth factor receptors by transforming growth factor beta in human osteoblastic MG-63 cells. J. Bone Miner. Res., 2002, 17:502-512

[349] Sabbieti MG et al. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. Endocrinology, 1999, 140:434-444

[350] Shao ES, Lin L, Yao Y, Bostrom KI. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood, 2009, 114:2197-2206

[351] Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature, 2014, 505:327-334

[352] Calvi LM et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 2003, 425:841-846

[353] Hsu YC, Fuchs E. A family business: stem cell progeny join the niche to regulate homeostasis. Nat. Rev. Mol. Cell Biol., 2012, 13:103-114

[354] Okabe M, Graham A. The origin of the parathyroid gland. Proc. Natl. Acad. Sci. USA, 2004, 101:17716-17719

[355] Bikle DD et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J. Bone Miner. Res., 2002, 17:1570-1578

[356] Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest., 1989, 83:60-65

[357] Lombardi G et al. Role of IGF-I on PTH effects on bone. J. Endocrinol. Invest., 2010, 33:22-26

[358] Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology, 2001, 142:4349-4356

[359] Pfeilschifter J et al. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J. Clin. Invest., 1995, 96:767-774

[360] Wan M et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev., 2008, 22:2968-2979

[361] Watson P et al. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone, 1995, 16:357-365

[362] Yu B et al. Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling. J. Bone Miner. Res., 2012, 27:2001-2014

[363] Polo S, Di Fiore PP. Endocytosis conducts the cell signaling orchestra. Cell, 2006, 124:897-900

[364] He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development, 2004, 131:1663-1677

[365] Itasaki N, Hoppler S. Crosstalk between Wnt and bone morphogenic protein signaling: a turbulent relationship. Dev. Dyn., 2010, 239:16-33

[366] Li C et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J. Bone Miner. Res., 2013, 28:2094-2108

[367] Jiang Y et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 2002, 418:41-49

[368] Kim SW et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J. Bone Miner. Res., 2012, 27:2075-2084

[369] Terauchi M et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab., 2009, 10:229-240

[370] Prisby R et al. Intermittent PTH(1-84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites. J. Bone Miner. Res., 2011, 26:2583-2596

[371] Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann. N. Y. Acad. Sci., 2010, 1192:230-237

[372] Newberry WN, Zukosky DK, Haut RC. Subfracture insult to a knee joint causes alterations in the bone and in the functional stiffness of overlying cartilage. J. Orthop. Res., 1997, 15:450-455

[373] Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage damage. Clin. Orthop. Relat. Res., 1986, 213:34-40

[374] Intema F et al. Similarities and discrepancies in subchondral bone structure in two differently induced canine models of osteoarthritis. J. Bone Miner. Res., 2010, 25:1650-1657

[375] Sniekers YH et al. A role for subchondral bone changes in the process of osteoarthritis; a micro-CT study of two canine models. BMC Musculoskelet. Disord., 2008, 9

[376] Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat. Rev. Rheumatol., 2012, 8:665-673

[377] Karsdal MA et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthr. Cartil., 2008, 16:638-646

[378] Grynpas MD, Alpert B, Katz I, Lieberman I, Pritzker KP. Subchondral bone in osteoarthritis. Calcif. Tissue Int., 1991, 49:20-26

[379] Huebner JL, Hanes MA, Beekman B, TeKoppele JM, Kraus VB. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. Osteoarthr. Cartil., 2002, 10:758-767

[380] Burr DB, Radin EL. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis? Rheum. Dis. Clin. North. Am., 2003, 29:675-685

[381] Ni GX et al. Matrix metalloproteinase-3 inhibitor retards treadmill running-induced cartilage degradation in rats. Arthritis Res. Ther., 2011, 13:R192

[382] Farquhar T et al. Swelling and fibronectin accumulation in articular cartilage explants after cyclical impact. J. Orthop. Res., 1996, 14:417-423

[383] Clements KM, Bee ZC, Crossingham GV, Adams MA, Sharif M. How severe must repetitive loading be to kill chondrocytes in articular cartilage? Osteoarthr. Cartil., 2001, 9:499-507

[384] Chen CT, Bhargava M, Lin PM, Torzilli PA. Time, stress, and location dependent chondrocyte death and collagen damage in cyclically loaded articular cartilage. J. Orthop. Res., 2003, 21:888-898

[385] Lin PM, Chen CT, Torzilli PA. Increased stromelysin-1 (MMP-3), proteoglycan degradation (3B3- and 7D4) and collagen damage in cyclically load-injured articular cartilage. Osteoarthr. Cartil., 2004, 12:485-496

[386] Serra R et al. Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J. Cell Biol., 1997, 139:541-552

[387] Yang X et al. TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol., 2001, 153:35-46

[388] van der Kraan PM, Goumans MJ, Blaney Davidson E, ten Dijke P. Age-dependent alteration of TGF-beta signalling in osteoarthritis. Cell Tissue Res., 2012, 347:257-265

[389] van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab. Invest., 1994, 71:279-290

[390] Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum., 2003, 48:3442-3451

[391] Warman ML et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am. J. Med. Genet. A, 2011, 155A:943-968

[392] Janssens K et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati–Engelmann disease. Nat. Genet., 2000, 26:273-275

[393] Kinoshita A et al. Domain-specific mutations in TGFB1 result in Camurati–Engelmann disease. Nat. Genet., 2000, 26:19-20

[394] Janssens K, ten Dijke P, Ralston SH, Bergmann C, Van Hul W. Transforming growth factor-beta 1 mutations in Camurati–Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J. Biol. Chem., 2003, 278:7718-7724

[395] Saito T et al. Domain-specific mutations of a transforming growth factor (TGF)-beta 1 latency-associated peptide cause Camurati–Engelmann disease because of the formation of a constitutively active form of TGF-beta 1. J. Biol. Chem., 2001, 276:11469-11472

[396] Janssens K et al. Camurati–Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J. Med. Genet., 2006, 43:1-11

[397] Whyte MP et al. Camurati–Engelmann disease: unique variant featuring a novel mutation in TGFbeta1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand. J. Bone Miner. Res., 2011, 26:920-933

[398] Bondestam J et al. Bone biopsy and densitometry findings in a child with Camurati–Engelmann disease. Clin. Rheumatol., 2007, 26:1773-1777

[399] Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nat. Genet., 1994, 6:64-69

[400] Dietz HC, Loeys B, Carta L, Ramirez F. Recent progress towards a molecular understanding of Marfan syndrome. Am. J. Med. Genet. C. Semin. Med. Genet., 2005, 139C:4-9

[401] Dietz HC et al. The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics, 1991, 9:355-361

[402] Dietz HC et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature, 1991, 352:337-339

[403] Neptune ER et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet., 2003, 33:407-411

[404] Loeys BL et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet., 2005, 37:275-281

[405] Gallo EM et al. Angiotensin II-dependent TGF-beta signaling contributes to Loeys–Dietz syndrome vascular pathogenesis. J. Clin. Invest., 2014, 124:448-460

[406] van de Laar IM et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat. Genet., 2011, 43:121-126

[407] Lindsay ME et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat. Genet., 2012, 44:922-927

[408] Carmignac V et al. In-frame mutations in exon 1 of SKI cause dominant Shprintzen–Goldberg syndrome. Am. J. Hum. Genet., 2012, 91:950-957

[409] Doyle AJ et al. Mutations in the TGF-beta repressor SKI cause Shprintzen–Goldberg syndrome with aortic aneurysm. Nat. Genet., 2012, 44:1249-1254

[410] Prunier C et al. The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation. J. Biol. Chem., 2003, 278:26249-26257

[411] Reed JA et al. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res., 2001, 61:8074-8078

[412] Nomura T et al. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev., 1999, 13:412-423

[413] Rhodes SD et al. Hyperactive transforming growth factor-beta1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J. Bone Miner. Res., 2013, 28:2476-2489

[414] Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res., 1997, 12:24-35

[415] Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol. Rev., 1985, 7:178-208

[416] Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest., 2005, 115:3318-3325

[417] Xu XH et al. Molecular genetic studies of gene identification for osteoporosis: the 2009 update. Endocr. Rev., 2010, 31:447-505

[418] Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone, 1997, 20:289-294

[419] Yamada Y et al. Association of the C-509-->T polymorphism, alone of in combination with the T869-->C polymorphism, of the transforming growth factor-beta1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women. J. Mol. Med., 2001, 79:149-156

[420] Yamada Y et al. Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res., 1998, 13:1569-1576

[421] Kou I et al. Common variants in a novel gene, FONG on chromosome 2q33.1 confer risk of osteoporosis in Japanese. PLoS ONE, 2011, 6:e19641

[422] Hubacek JA et al. No associations between genetic polymorphisms of TGF-beta, PAI-1, and COL1A1, and bone mineral density in Caucasian females. Endocr. Regul., 2006, 40:107-112

[423] Tural S et al. Association between osteoporosis and polymorphisms of the IL-10 and TGF-beta genes in Turkish postmenopausal women. Hum. Immunol., 2013, 74:1179-1183

[424] Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 293:L525-534

[425] Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci., 2002, 7:d793-807

[426] Zeisberg EM et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med., 2007, 13:952-961

[427] Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J. Clin. Investig., 1990, 86:453-462

[428] Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int., 1992, 42:1462-1469

[429] Kagami S, Border WA, Ruoslahti E, Noble NA. Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab. Invest., 1993, 69:68-76

[430] Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature, 1990, 346:371-374

[431] Border WA et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature, 1992, 360:361-364

[432] Isaka Y et al. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest., 1993, 92:2597-2601

[433] Lee HS. Pathogenic role of TGF-beta in the progression of podocyte diseases. Histol. Histopathol., 2011, 26:107-116

[434] Chen HC et al. Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci., 2000, 67:2345-2353

[435] Das F, Ghosh-Choudhury N, Kasinath BS, Choudhury GG. TGF beta enforces activation of eukaryotic elongation factor-2 (eEF2) via inactivation of eEF2 kinase by p90 ribosomal S6 kinase (p90Rsk) to induce mesangial cell hypertrophy. FEBS Lett., 2010, 584:4268-4272

[436] Abdel-Wahab N, Weston BS, Roberts T, Mason RM. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol., 2002, 13:2437-2445

[437] Rodriguez-Barbero A et al. TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. Kidney Int., 2006, 70:901-909

[438] Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol., 2008, 19:2282-2287

[439] Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest., 2003, 112:1486-1494

[440] Li J et al. Blockade of endothelial–mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes, 2010, 59:2612-2624

[441] Garcia-Sanchez O, Lopez-Hernandez FJ, Lopez-Novoa JM. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int., 2010, 77:950-955

[442] Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat. Rev. Nephrol., 2009, 5:319-328

[443] Meran S, Steadman R. Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol., 2011, 92:158-167

[444] Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol., 2003, 200:500-503

[445] LeBleu VS et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med., 2013, 19:1047-1053

[446] Brenner DA. Molecular pathogenesis of liver fibrosis. Trans. Am. Clin. Climatol. Assoc., 2009, 120:361-368

[447] Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med., 1991, 324:933-940

[448] Nagy P, Schaff Z, Lapis K. Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. Hepatology, 1991, 14:269-273

[449] Czaja MJ et al. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J. Cell Biol., 1989, 108:2477-2482

[450] Ueberham E et al. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology, 2003, 37:1067-1078

[451] Ueno H et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum. Gene Ther., 2000, 11:33-42

[452] Dooley S, ten Dijke P. TGF-beta in progression of liver disease. Cell Tissue Res., 2012, 347:245-256

[453] Hayashi H, Sakai T. Biological significance of local TGF-beta activation in liver diseases. Front. Physiol., 2012, 3:12

[454] Carr BI, Hayashi I, Branum EL, Moses HL. Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res., 1986, 46:2330-2334

[455] Oberhammer FA et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA, 1992, 89:5408-5412

[456] Jiang JX et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology, 2010, 139:1375-1384

[457] Dooley S et al. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGF beta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett., 2001, 502:4-10

[458] Hu T et al. Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am. J. Physiol. Ren. Physiol., 2005, 289:F816-825

[459] Westergren-Thorsson G et al. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. J. Clin. Invest., 1993, 92:632-637

[460] Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA, 1991, 88:6642-6646

[461] Deguchi Y. Spontaneous increase of transforming growth factor beta production by bronchoalveolar mononuclear cells of patients with systemic autoimmune diseases affecting the lung. Ann. Rheum. Dis., 1992, 51:362-365

[462] Khalil N, Whitman C, Zuo L, Danielpour D, Greenberg A. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J. Clin. Invest., 1993, 92:1812-1818

[463] Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am. Fam. Phys., 2008, 78:961-968

[464] Ghahary A, Shen YJ, Scott PG, Gong Y, Tredget EE. Enhanced expression of mRNA for transforming growth factor-beta, type I and type III procollagen in human post-burn hypertrophic scar tissues. J. Lab. Clin. Med., 1993, 122:465-473

[465] Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N. Eng. J. Med., 1994, 331:1286-1292

[466] Loeys BL et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci. Transl. Med., 2010, 2:23ra20

[467] Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature, 2011, 473:308-316

[468] Gerber EE et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature, 2013, 503:126-130

[469] Munger JS, Sheppard D. Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb. Perspect. Biol., 2011, 3:a005017

[470] Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet, 1992, 339:213-214

[471] Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax, 1993, 48:959-966

[472] Logan A et al. Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur. J. Neurosci., 1994, 6:355-363

[473] Wahl SM, Allen JB, Costa GL, Wong HL, Dasch JR. Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J. Exp. Med., 1993, 177:225-230

[474] Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J. Clin. Invest., 1994, 93:1172-1178

[475] Gupta GP, Massague J. Cancer metastasis: building a framework. Cell, 2006, 127:679-695

[476] van der Pluijm G et al. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J. Bone Miner. Res., 2001, 16:1077-1091

[477] Mohan S, Baylink DJ. Bone growth factors. Clin. Orthop. Relat. Res., 1991, 263:30-48

[478] Juarez P, Guise TA. TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone, 2011, 48:23-29

[479] Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer, 2003, 3:807-821

[480] Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet., 2001, 29:117-129

[481] Massague J. TGF beta in cancer. Cell, 2008, 134:215-230

[482] Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev., 1996, 7:93-102

[483] Park K et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc. Natl. Acad. Sci. USA, 1994, 91:8772-8776

[484] Ohue M et al. Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer. Int. J. Cancer, 1996, 68:203-206

[485] Izumoto S et al. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett., 1997, 112:251-256

[486] Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res., 1998, 58:4805-4810

[487] Chen T et al. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res., 2001, 61:4679-4682

[488] Goggins M et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res., 1998, 58:5329-5332

[489] Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood, 1999, 94:2854-2861

[490] Eppert K et al. MADR2 maps to 18q21 and encodes a TGF beta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell, 1996, 86:543-552

[491] Takagi Y et al. Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br. J. Cancer, 1998, 78:1152-1155

[492] Schutte M et al. DPC4 gene in various tumor types. Cancer Res., 1996, 56:2527-2530

[493] Howe JR et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science, 1998, 280:1086-1088

[494] Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene, 1999, 18:4879-4883

[495] Daly AC, Vizan P, Hill CS. Smad3 protein levels are modulated by Ras activity and during the cell cycle to dictate transforming growth factor-beta responses. J. Biol. Chem., 2010, 285:6489-6497

[496] Jones S et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008, 321:1801-1806

[497] Leary RJ et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. USA, 2008, 105:16224-16229

[498] Iavarone A, Lasorella A. ID proteins as targets in cancer and tools in neurobiology. Trends Mol. Med., 2006, 12:588-594

[499] Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit. Rev. Oncog., 1999, 10:303-360

[500] Padua D, Massague J. Roles of TGF beta in metastasis. Cell Res., 2009, 19:89-102

[501] Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (review). Int. J. Oncol., 2001, 18:669-681

[502] Pertovaara L et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem., 1994, 269:6271-6274

[503] Kang Y et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3:537-549

[504] de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J. Pathol., 1998, 184:53-57

[505] Hasegawa Y et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer, 2001, 91:964-971

[506] Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res., 2002, 62:6021-6025

[507] Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell, 2005, 8:369-380

[508] Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med., 2001, 7:1118-1122

[509] Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med., 2009, 1:303-314

[510] Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene, 2005, 24:5764-5774

[511] Batlle E et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol., 2000, 2:84-89

[512] Cano A et al. The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol., 2000, 2:76-83

[513] Boutet A et al. Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J., 2006, 25:5603-5613

[514] Lyons JG et al. Snail upregulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res., 2008, 68:4525-4530

[515] Henderson MA et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res., 2006, 66:2250-2256

[516] Thomas RJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 1999, 140:4451-4458

[517] Kakonen SM et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J. Biol. Chem., 2002, 277:24571-24578

[518] Yin JJ et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest., 1999, 103:197-206

[519] Guise TA et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest., 1996, 98:1544-1549

[520] Dunn LK et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE, 2009, 4:e6896

[521] Kang Y, Massague J. Epithelial–mesenchymal transitions: twist in development and metastasis. Cell, 2004, 118:277-279

[522] Korpal M et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med., 2009, 15:960-966

[523] Kang Y et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA, 2005, 102:13909-13914

[524] Deckers M et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res., 2006, 66:2202-2209

[525] Javelaud D et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res., 2007, 67:2317-2324

[526] Bandyopadhyay A et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res., 2006, 66:6714-6721

[527] Ehata S et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci., 2007, 98:127-133

[528] Biswas S et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest., 2007, 117:1305-1313

[529] Nam JS et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res., 2008, 68:3835-3843

[530] Biswas S et al. Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS ONE, 2011, 6:e27090

[531] Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res., 2007, 67:4157-4163

[532] Lu X et al. In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res., 2010, 70:3905-3914

[533] McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J. Biol. Chem., 2006, 281:24171-24181

[534] Juarez P et al. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res., 2012, 72:6247-6256

[535] Ganapathy V et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer, 2010, 9

[536] Bouquet F et al. TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res., 2011, 17:6754-6765

[537] Schlingensiepen R et al. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides, 2005, 15:94-104

[538] Schlingensiepen KH et al. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev., 2006, 17:129-139

[539] Jachimczak P et al. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg., 1993, 78:944-951

[540] Schlingensiepen KH et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci., 2011, 102:1193-1200

[541] Bogdahn U et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. NeuroOncology, 2011, 13:132-142

[542] Santiago B et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol., 2005, 125:450-455

[543] Llopiz D et al. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int. J. Cancer, 2009, 125:2614-2623

[544] Hermida N et al. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc. Res., 2009, 81:601-609

[545] Ezquerro IJ et al. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine, 2003, 22:12-20

[546] Denton CP et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum., 2007, 56:323-333

[547] Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci., 2003, 44:3394-3401

[548] .. CAT-152 trabeculectomy study. Ophthalmology, 2007, 114:1950

[549] Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-beta in cancer patients. Curr. Pharm. Biotechnol., 2011, 12:2176-2189

[550] Trachtman H et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int., 2011, 79:1236-1243

[551] Morris JC et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF beta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE, 2014, 9:e90353

[552] Van Aarsen LA et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res., 2008, 68:561-570

[553] Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res., 2008, 177:137-150

[554] Hau P et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides, 2007, 17:201-212

[555] Ramfidis VS, Strimpakos AS, Syrigos KN, Saif MW. Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress? J. Pancreas, 2012, 13:358-360

[556] Nemunaitis J et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol., 2006, 24:4721-4730

[557] Nemunaitis J et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther., 2009, 16:620-624

[558] Giaccone G et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur. J. Cancer, 2015, 51:2321-2329

[559] Muraoka RS et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest., 2002, 109:1551-1559

[560] Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov., 2004, 3:1011-1022

[561] Bonafoux D, Lee WC. Strategies for TGF-beta modulation: a review of recent patents. Expert Opin. Ther. Pat., 2009, 19:1759-1769

[562] Easty D, Gallagher W, Bennett DC. Protein tyrosine phosphatases, new targets for cancer therapy. Curr. Cancer Drug Targets, 2006, 6:519-532

[563] Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr. Opin. Investig. Drugs, 2006, 7:513-521

[564] Habashi JP et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006, 312:117-121

[565] Cohn RD et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med., 2007, 13:204-210

[566] Podowski M et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J. Clin. Invest., 2012, 122:229-240

[567] Lanz TV et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J. Clin. Invest., 2010, 120:2782-2794

[568] Zhou H, Latham CW, Zander DS, Margolin SB, Visner GA. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J. Heart Lung Transplant., 2005, 24:1577-1585

[569] Taniguchi H et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir. Res., 2011, 12:93

[570] Noble PW et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 2011, 377:1760-1769

[571] Chen HY et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes, 2011, 60:590-601

[572] Kapoor S. Smad7 gene transfer therapy: therapeutic applications beyond colonic fibrosis. Eur. J. Clin. Invest., 2008, 38:876-877

[573] Sheridan C. Gene therapy finds its niche. Nat. Biotechnol., 2011, 29:121-128

[574] Zhu S et al. Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats. Bone, 2013, 53:340-349

[575] Panahifar A, Maksymowych WP, Doschak MR. Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthr. Cartil., 2012, 20:694-702

[576] Shirai T et al. Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J. Orthop. Res., 2011, 29:1572-1577

[577] Zhang L, Hu H, Tian F, Song H, Zhang Y. Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. Clin. Exp. Med., 2011, 11:235-243

[578] Hayami T et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum., 2004, 50:1193-1206

[579] Nishii T, Tamura S, Shiomi T, Yoshikawa H, Sugano N. Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. Clin. Rheumatol., 2013, 32:1759-1766

[580] Carbone LD et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum., 2004, 50:3516-3525

[581] Jilka RL et al. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell, 2010, 9:851-867

[582] Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest., 2008, 118:421-428

[583] Orth P et al. Parathyroid hormone [1-34] improves articular cartilage surface architecture and integration and subchondral bone reconstitution in osteochondral defects in vivo. Osteoarthr. Cartil., 2013, 21:614-624

[584] Sampson ER et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci. Transl. Med., 2011, 3:101ra193

[585] Bellido M et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthr. Cartil., 2011, 19:1228-1236

[586] Smith JN, Calvi LM. Concise review: current concepts in bone marrow microenvironmental regulation of hematopoietic stem and progenitor cells. Stem Cells, 2013, 31:1044-1050

[587] Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-beta - an excellent servant but a bad master. J. Transl. Med., 2012, 10